

SUPPLEMENTARY DATA


**Supplementary Table 1.** Distribution of the final daily Gla-100 doses at Week 24 LOCF (safety population)

Final Gla-100 dose, <i>n</i> (%)	LixiLan ( <i>n</i> = 161)	Gla-100 ( <i>n</i> = 162)
≤20 U	23 (14)	16 (10)
>20 to ≤40 U	70 (44)	73 (45)
>40 to ≤60 U	68 (42)	46 (28)
>60 U	N/A	27 (17)

LOCF, last observation carried forward; N/A, not applicable; U, units.


SUPPLEMENTARY DATA

Supplementary Figure 1. Study design



SUPPLEMENTARY DATA

**Supplementary Figure 2.** Summary of patient disposition



## SUPPLEMENTARY DATA

### List of Principal Study Investigators

Chile: María L. Aguirre, Juan G. Godoy, Vicente Gutierrez, Rodolfo Lahsen, Néstor Soto; Czech Republic: Martin Haluzik, Petra Horanska, Vladimír Polák, Jitka Zemanova; Denmark: Jesper O. Christensen, **Jørgen Hangaard**, Henning F. Juhl, Hans Perrild; France: Jean-Pierre Courreges, Bruno Guerci, Samy Hadjadj; Germany: Annette Chen-Stute, Frank Schaper, Lutz Stemler; Hungary: Gábor Holzinger, Zsuzsanna Kerényi, Laszlo I. Koranyi, Csaba Lengyel, Gizella Petró, Albert Szocs; Lithuania: Lina Barsiene, Lina Radzeviciene, Sigitas Stonkus, Birute Zilaitiene; Mexico: Raul A. Aguilar-Orozco, Cesar G. Calvo-Vargas, Aniceto Leguizamo-Dimas, Leobardo Sauque-Reyna, Rolando Zamarripa-Escobedo; Poland: Malgorzata Arciszewska, Grazyna Ciesliek, Elwira Gromniak, Ewa Gross-Tyrkin, Krystyna Jedynasty, Marek Konieczny, Anna Mikolajczyk-Swatko; Romania: Adriana Cif, Ioana E. Ferariu, Mircea Munteanu, Alina Nicolau, Adriana G. Onaca, Ella Pintilei; Slovakia: Ingrid Bugánova, Viera Donicová, Edita Fedurcová, Adriana Ilavská, Iveta Marková, Zbynek Schroner; Sweden: Michael Alvarsson, Lars Henningsson, Karl E.O. Ljungström; United States: Ronald L. Brazg, John B. Buse, Lisa Connery, Jose Mari L. Elacion, Neil R. Farris, Edward M. Kerwin, Samer Nakhle, Adeniyi O. Odugbesan, Robert Ratner, John C.H. Reed, Helena W. Rodbard, Brian Snyder, James R. Thrasher.